Select Investment Series III - T. Rowe Price Health Sciences Equity Fund Q Fonds
10,34
USD
+0,29
USD
+2,89
%
NAV
Werbung
Anlageziel
To increase the value of its shares, over the long term, through growth in the value of, and income from, its investments. The fund is actively managed and invests mainly in a diversified portfolio of shares of companies that are involved in the research, development, production, or distribution of products or services related to health sciences. The companies may be anywhere in the world, including emerging markets, with a focus on companies in the United States.
Stammdaten
| Name | Select Investment Series III SICAV - T. Rowe Price Health Sciences Equity Fund Q Fonds |
| ISIN | LU2349435961 |
| WKN | A3C5BC |
| Fondsgesellschaft | T. Rowe Price (Luxembourg) Management S.à r.l. |
| Benchmark | Russell 3000 Ind/HC |
| Ausschüttungsart | Thesaurierend |
| Manager | Ziad Bakri |
| Domizil | Luxembourg |
| Fondskategorie | Aktien |
| Auflagedatum | 08.11.2021 |
| Geschäftsjahr | 31.12. |
| VL-fähig? | Nein |
| Depotbank | J.P. Morgan SE, Luxembourg Branch |
| Zahlstelle | |
| Riester Fonds | Nein |
Basisdaten
| Auflagedatum | 08.11.2021 |
| Depotbank | J.P. Morgan SE, Luxembourg Branch |
| Zahlstelle | |
| Domizil | Luxembourg |
| Geschäftsjahr | 31.12. |
Aktuelle Daten
| Morningstar Rating | |
| Aktueller Rücknahmepreis | 10,34 |
| Anzahl Fonds der Kategorie | 820 |
| Volumen der Tranche | 24,86 Mio. USD |
| Fondsvolumen | 51,67 Mio. USD |
| Total Expense Ratio (TER) | 0,95 |
Gebühren
| Laufende Kosten | 1,22% |
| Total Expense Ratio (Verwaltungsgebühren & sonst. Kosten) | 0,95% |
| Transaktionskosten | 0,27% |
| Depotbankgebühr | - |
| Managementgebühr | 0,84% |
| Rücknahmegebühr | - |
| Ausgabeaufschlag | - |
Performancedaten
| Veränderung Vortag | 0,29 |
| WE seit Jahresbeginn | 16,57% |